The China Mail - Ketamine pill treats depression without psychedelic effects: study

USD -
AED 3.673042
AFN 72.000368
ALL 87.274775
AMD 390.940403
ANG 1.80229
AOA 912.000367
ARS 1137.970104
AUD 1.565349
AWG 1.8
AZN 1.70397
BAM 1.720686
BBD 2.017877
BDT 121.428069
BGN 1.721593
BHD 0.376901
BIF 2930
BMD 1
BND 1.312071
BOB 6.906563
BRL 5.808204
BSD 0.999437
BTN 85.314611
BWP 13.77569
BYN 3.270808
BYR 19600
BZD 2.007496
CAD 1.384165
CDF 2877.000362
CHF 0.81849
CLF 0.025203
CLP 967.160396
CNY 7.30391
CNH 7.30369
COP 4310
CRC 502.269848
CUC 1
CUP 26.5
CVE 97.403894
CZK 22.038604
DJF 177.720393
DKK 6.56557
DOP 60.503884
DZD 132.56604
EGP 51.126904
ERN 15
ETB 133.023649
EUR 0.879325
FJD 2.283704
FKP 0.754396
GBP 0.753835
GEL 2.740391
GGP 0.754396
GHS 15.56039
GIP 0.754396
GMD 71.503851
GNF 8655.503848
GTQ 7.698128
GYD 209.656701
HKD 7.763675
HNL 25.908819
HRK 6.612104
HTG 130.419482
HUF 359.10504
IDR 16862.9
ILS 3.68639
IMP 0.754396
INR 85.377504
IQD 1310
IRR 42125.000352
ISK 127.590386
JEP 0.754396
JMD 157.965583
JOD 0.709304
JPY 142.384504
KES 129.503801
KGS 87.233504
KHR 4015.00035
KMF 433.503794
KPW 900.005534
KRW 1418.390383
KWD 0.30663
KYD 0.832893
KZT 523.173564
LAK 21630.000349
LBP 89600.000349
LKR 298.915224
LRD 199.975039
LSL 18.856894
LTL 2.95274
LVL 0.60489
LYD 5.470381
MAD 9.275039
MDL 17.289555
MGA 4552.892736
MKD 54.091003
MMK 2099.41494
MNT 3537.11356
MOP 7.990393
MRU 39.435529
MUR 45.090378
MVR 15.403739
MWK 1736.000345
MXN 19.71941
MYR 4.407504
MZN 63.905039
NAD 18.856894
NGN 1604.703725
NIO 36.775056
NOK 10.47246
NPR 136.503202
NZD 1.67405
OMR 0.384998
PAB 0.999437
PEN 3.763039
PGK 4.133235
PHP 56.712504
PKR 280.603701
PLN 3.762405
PYG 7999.894426
QAR 3.640604
RON 4.378104
RSD 103.137317
RUB 82.174309
RWF 1415
SAR 3.752237
SBD 8.368347
SCR 14.241693
SDG 600.503676
SEK 9.62027
SGD 1.310745
SHP 0.785843
SLE 22.775038
SLL 20969.483762
SOS 571.503662
SRD 37.15037
STD 20697.981008
SVC 8.745073
SYP 13002.282567
SZL 18.820369
THB 33.347038
TJS 10.733754
TMT 3.5
TND 2.988038
TOP 2.342104
TRY 38.020804
TTD 6.781391
TWD 32.524038
TZS 2687.503631
UAH 41.417687
UGX 3663.55798
UYU 41.913007
UZS 12986.521678
VES 80.85863
VND 25870
VUV 122.04998
WST 2.787364
XAF 577.111964
XAG 0.03066
XAU 0.000301
XCD 2.70255
XDR 0.717698
XOF 575.000332
XPF 102.775037
YER 245.250363
ZAR 18.821904
ZMK 9001.203587
ZMW 28.458439
ZWL 321.999592
  • VOD

    0.1400

    9.31

    +1.5%

  • AZN

    0.5400

    67.59

    +0.8%

  • SCS

    0.0500

    9.76

    +0.51%

  • GSK

    0.5600

    35.93

    +1.56%

  • NGG

    0.6300

    72.11

    +0.87%

  • RBGPF

    63.5900

    63.59

    +100%

  • RYCEF

    -0.1400

    9.36

    -1.5%

  • CMSC

    0.0400

    21.82

    +0.18%

  • BTI

    0.5400

    42.37

    +1.27%

  • RIO

    1.0100

    58.17

    +1.74%

  • CMSD

    0.0400

    21.96

    +0.18%

  • BCE

    0.4200

    22.04

    +1.91%

  • JRI

    0.1600

    12.4

    +1.29%

  • BCC

    0.7800

    93.47

    +0.83%

  • RELX

    1.0000

    52.2

    +1.92%

  • BP

    0.6600

    28.32

    +2.33%

Ketamine pill treats depression without psychedelic effects: study
Ketamine pill treats depression without psychedelic effects: study / Photo: © AFP/File

Ketamine pill treats depression without psychedelic effects: study

A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.

Text size:

First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".

However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.

In many countries, ketamine has been prescribed for depression for years.

US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".

The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.

Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.

There are also fears that medical use of the drug could slide into abuse.

The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.

"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.

"I don't think these tablets would appeal to people who are abusing ketamine."

- Electro-shock alternative -

The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.

More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.

Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.

Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.

Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.

"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.

This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.

But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".

- Fears of 'opioid style crisis' -

Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.

Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.

US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.

One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.

But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.

By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.

There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.

More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.

O.Tse--ThChM